News

Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.

For CVI Awareness Day, 3 experts explain why CVI can hide behind a normal eye exam and why early referral matters.

Coats, OD, FAAO, explains how neurotrophic keratitis, demodex, cosmetic habits and mucus fishing complicate dry eye disease.

Veeral S. Sheth, MD, MBA, FACS, FASRS, on how the avacincaptad pegol label update, earlier treatment, and patient counseling shape long-term GA care.

Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.

Cathleen McCabe, MD, presents real-world data from a 57-site US study of the enVista Aspire IOL at ESCRS 2026, reporting over 90% patient satisfaction and 20/32 uncorrected intermediate vision in more than 70% of patients.

Nimesh A. Patel, MD, explains why myopia-related retinal detachments are appearing earlier and how routine exams can catch them.

Alessandro Arrigo, MD, describes an early-stage method that uses blue light autofluorescence imaging to grade cataracts objectively. He explains why a reproducible score could help with surgeon selection, IOL power calculation, and retinal image quantification.

A multimodal OCT and ultra-widefield imaging model detected retinal inflammation in uveitis without fluorescein dye.

Nimesh A. Patel, MD, discusses compounded low-dose atropine and SYD-101 ahead of an October 30 FDA advisory committee meeting.

Christina Y. Weng, MD, MBA, FASRS, highlights findings showing statin use reduced PVR risk by 25% in a propensity-matched cohort of nearly 10,000 patients.

At Retina Society 2026, Emily Eton, MD, discusses a 10-center study finding similar exudate control in Coats disease and Coats-like disease in inherited retinal diseases, with more injections needed in the IRD group.

Non-invasive electrical stimulation delivered through closed eyelids improved retinal structure and photoreceptor function.

Jesse L. Berry, MD, discusses prospective data on aqueous humor liquid biopsy in retinoblastoma and explains how molecular markers from the aqueous are beginning to guide recurrence risk, treatment intensity, and the workup of otherwise diagnostically inaccessible intraocular lesions.

In the latest episode of The Retina TL;DR with Dr. Weng—part 1 of a special two-part series—host Christina Y. Weng, MD, MBA, FASRS, sits down with two of her former residents, now second-year surgical retina fellows, for candid advice on matching, transitioning, and thriving in fellowship.

At Retina Society 2026, Eileen Hwang, MD, PhD, discusses a meta-analysis finding a 1.78 times higher retinal detachment rate in COL2A1 vs COL11A1 Stickler syndrome and the case for prophylactic laser.

At Retina Society 2026, Nimesh Patel, MD, discusses how stage 2 ROP before 34 weeks raises the treatment rate and why he urges early referral and a risk-tailored approach to care.

Concurrent exudative disease, early intervention, and a rare masquerader complicate the classic picture of geographic atrophy.

Charles Wykoff, MD, PhD, reviews LUGANO safety and treatment burden data, including a 42% injection reduction with vorolanib insert vs aflibercept, despite a missed primary end point.

Three residents were honored for their leadership, education and research, and patient care contributions in ophthalmology, optometry, and retina.

Patient enrollment is complete in the the ASTRA phase 3 study AURN001 to treat corneal edema associated with corneal endothelial dysfunction.

Subretinal deposits are linked to worse surgical risks in patients with severe aortic stenosis and reduced systemic blood flow.

Mark P. Breazzano, MD, FACS, shares findings from a TriNetX real-world database analysis on how HIV co-infection influences RPR titers in patients with ocular syphilis.

Chhablani reports revakinagene taroretcel-lwey slowed cavitation volume growth and preserved photoreceptor structure in MacTel type 2.

Dilsher S. Dhoot, MD, FASRS, breaks down the Phase 3 SOL-1 results on intravitreal axitinib hydrogel (OTX-TKI) and aflibercept on vision maintenance.

Talisa Forest (de Carlo), MD, discusses how dynamic complement biomarkers track with artificial intelligence-measured geographic atrophy progression.

K. Thiran Jayasundera, MD, MS, FACS, on how patient interviews shaped a tool capturing functional and psychological burdens overlooked by visual acuity.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.